Skip to main content
SpringerLink
Log in

Lipid metabolism alteration and treatment in heart transplant recipients

  • Chapter
Late Graft Loss

Part of the book series: Transplantation and Clinical Immunology ((TRAC,volume 28))

  • 67 Accesses

Abstract

Acute rejection and various infections are the most common causes of fatal and nonfatal complications within the first year after cardiac transplantation. Because of the progressive adaptation that occurs by the host to the graft, the incidence of acute rejection diminishes with time and immunosuppression can be reduced. The incidence of infection therefore also lessens. Consequently, the predominant cause of graft loss after the first year is the development of accelerated obstructive coronary atherosclerosis [1]. All organ grants are affected by this kind of graft vasculopathy (GV) but nowhere is the effect as serious as in heart transplantation with the cardiac muscle particularly dependent on an unimpeded blood supply and the patient on the graft.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Forrat R, Ferrera R, Boissonnat P et al. High prevalence of thromboembolic complications in heart transplant recipients. Transplantation 1996; 61: 757–762.

    Article  PubMed  CAS  Google Scholar 

  2. Johnson DE, Gao SZ, Schroeder JS, DeCampli WM, Billingham ME. The spectrum of coronary artery pathologic findings in human cardiac allografts. J. Heart Transplant. 1989; 8: 349–359.

    PubMed  CAS  Google Scholar 

  3. Keogh AM, Valantine HA, Hunt SA et al. Impact of proximal or midvessel discrete coronary artery stenoses on survival after heart transplantation. J. Heart Lung Transplant. 1992; 11: 892–901.

    PubMed  CAS  Google Scholar 

  4. de Lorgeril M, Loire R, Guidollet J, Boissonnat P, Dureau G, Renaud S. Accelerated coronary artery disease after heart transplantation: the role of enhanced platelet aggregation and thrombosis. J. Int. Med. 1993; 233: 343–350.

    Article  Google Scholar 

  5. Labarrere CA, Pitts D, Nelson DR, Faulk WP. Vascular tissue plasminogen activator and the development of coronary artery disease in heart-transplant recipients. N. Engl. J. Med. 1995; 333: 1111–1116.

    Article  PubMed  Google Scholar 

  6. de Lorgeril M, Boissonnat P, Mamelle N et al. Platelet aggregation and HDL cholesterol are predictive of acute coronary events in heart transplant recipients. Circulation 1994; 89: 2590–2594.

    Article  PubMed  Google Scholar 

  7. Uretsky B, Murali S, Reddy P et al. Development of coronary artery disease in cardiac transplant recipients receiving immunosuppressive therapy with cyclosporin and prednisone. Circulation 1987; 76: 827–834.

    Article  PubMed  CAS  Google Scholar 

  8. de Groen PC. Cyclosporin, low-density lipoprotein, and cholesterol. Mayo Clin. Proc. 1988; 63: 1012–1021.

    Article  Google Scholar 

  9. Kobashigawa JA, Katznelson S, Laks H et al. Effect of pravastatin on outcomes after cardiac transplantation. N. Engl. J. Med. 1995; 333: 621–627.

    Article  PubMed  CAS  Google Scholar 

  10. McPherson R, Tsoukas C, Baines MG et al. Effects of lovastatin on natural killer cell function and other immunological parameters in man. J. Clin. Immunol. 1993; 13: 439–444.

    Article  PubMed  CAS  Google Scholar 

  11. Yui Y, Aoyama T, Morishita H et al. Serum prostacyclin stabilizing factor is identical to apolipoprotein Al: a novel function of apo Al. J. Clin. Invest. 1998; 82: 803–807.

    Article  Google Scholar 

  12. Bordet JC, de Lorgeril M, Durbin S et al. Evaluation of renal and systemic production of prostacyclin in cyclosporin-treated heart transplant recipients. Am. J. Cardiol. 1993; 72: 486–487.

    Article  PubMed  CAS  Google Scholar 

  13. Webb AT, Reaveley DA, O’Donnell M, O’Connor B, Seed M, Brown EA. Does cyclosporin increase lipoprotein (a) concentrations in renal transplant recipients? Lancet 1993; 341: 268–270.

    Article  PubMed  CAS  Google Scholar 

  14. Farmer JA, Ballantyne CM, Frazier OH et al. Lipoprotein (a) and apolipoprotein changes after cardiac transplantation. JACC 1991; 18: 926–930.

    Article  PubMed  CAS  Google Scholar 

  15. Barbir M, Kushwaha S, Hunt B et al. Lipoprotein (a) and accelerated coronary artery disease in cardiac transplant recipients. Lancet 1992; 340: 1500–1502.

    Article  PubMed  CAS  Google Scholar 

  16. Boissonnat P, Salen P, Guidollet J et al. The long-term effects of the lipid-lowering agent fenofibrate in hyperlipidemic heart transplant recipients. Transplantation 1994; 58: 245–247.

    PubMed  CAS  Google Scholar 

  17. de Lorgeril M, Dureau G, Guidollet J, Boissonnat P, Renaud S. Prevalence of dyslipidemias in long-term survivors of heart transplantation. Eur. Heart J. 1990; 11: 176.

    Google Scholar 

  18. Keogh A, Simons L, Spratt P et al. Hyperlipidemia after heart transplantation. J. Heart Transplant. 1988; 7: 171–175.

    PubMed  CAS  Google Scholar 

  19. Johnson MR. Transplant coronary disease: nonimmunologic risk factors. J. Heart Lung Transplant. 1992; 11: S124–S132.

    PubMed  CAS  Google Scholar 

  20. Grady KL, Costanzo-Nordin MR, Herold LS, Sriniavasan S, Pifarre R. Obesity and hyperlipidemia after heart transplantation. J. Heart Lung Transplant. 1991; 10: 449–454.

    PubMed  Google Scholar 

  21. Laufer G, Grablowitz V, Laczkovics A et al. The determinants of elevated total plasma cholesterol levels in cardiac transplant recipients administered low dose cyclosporin for immunosuppression. J. Thorac. Cardiovasc. Surg. 1992; 104: 241–247.

    PubMed  CAS  Google Scholar 

  22. Salen P, de Lorgeril M, Boissonnat P et al. Effects of French mediterranean diet on heart transplant recipients with hypercholesterolemia. Am. J. Cardiol. 1994; 73: 825–827.

    Article  PubMed  CAS  Google Scholar 

  23. Miller LW. Steroid withdrawal in heart transplantation: Editorial. J. Heart Lung Transplant. 1992; 11: 401–402.

    PubMed  CAS  Google Scholar 

  24. Renlund DG, Bristow MR, Crandall BG et al. Hypercholesterolemia after heart transplantation: amelioration by corticosteroid-free maintenance immunosuppression. J. Heart Transplant. 1989; 8: 214–220.

    PubMed  CAS  Google Scholar 

  25. Pritzker MR, Lake KD, Reutzel TJ et al. Steroid-free maintenance immunotherapy: Minneapolis Heart Institute experience. J. Heart Lung Transplant. 1992; 11: 415–420.

    PubMed  CAS  Google Scholar 

  26. Hricik DE, Bartucci MR, Mayes JT, Schulak JA. The effects of steroid withdrawal on the lipoprotein profiles of cyclosporin-treated kidney and kidney—pancreas transplant recipients. Transplantation 1992; 54: 868–871.

    Article  PubMed  CAS  Google Scholar 

  27. Asai K, Funaki C, Hayashi T et al. Dexamethasone-induced suppression of aortic atherosclerosis in cholesterol-fed rabbits. Possible mechanisms. Arteriosclerosis Thromb. 1993; 13: 892–899.

    Article  CAS  Google Scholar 

  28. Superko HR, Haskell WL, Di Ricco CD. Lipoprotein and hepatic lipase activity and high-density lipoprotein subclasses after cardiac transplantation. Am. J. Cardiol. 1990; 66: 1131–1134.

    Article  PubMed  CAS  Google Scholar 

  29. Atger V, Cambillau M, Guillemain R et al. Serum lipid abnormalities in heart transplant recipients: predominance of HDL2-like particles in the HDL pattern. Atherosclerosis 1990; 81: 103–110.

    Article  PubMed  CAS  Google Scholar 

  30. Chancerelle Y, de Lorgeril M, Viret R et al. Increased lipid peroxidation in cyclosporin-treated heart transplant recipients. Am. J. Cardiol. 1991; 68: 813–816.

    Article  PubMed  CAS  Google Scholar 

  31. Taylor JE, Scott N, Hill A et al. Oxygen free radicals and platelet and granulocyte aggregability in renal transplant patients. Transplantation 1993; 55: 500–504.

    Article  PubMed  CAS  Google Scholar 

  32. Ardlie NG, Selley ML, Simmons LA. Platelet activation by oxidatively modified low density lipoproteins. Atherosclerosis 1989; 76: 117–124.

    Article  PubMed  CAS  Google Scholar 

  33. de Lorgeril M, Dureau G, Boissonnat P et al. Platelet function and composition in heart transplant recipients compared with nontransplanted coronary patients. Arteriosclerosis Thromb. 1992; 12: 222–230.

    Article  Google Scholar 

  34. de Lorgeril M, Dureau G, Boissonnat P et al. Increased platelet aggregability after heart transplantation: influence of aspirin. J. Heart Lung Transplant. 1991; 10: 600–603.

    PubMed  Google Scholar 

  35. de Lorgeril M, Richard MJ, Arnaud J et al. Lipid peroxides and antioxidant defenses in accelerated transplantation-associated coronary arteriosclerosis. Am. Heart J. 1993; 125: 974–980.

    Article  PubMed  Google Scholar 

  36. de Lorgeril M, Boissonnat P, Salen P et al. The beneficial effect of dietary antioxidant supplementation on platelet aggregation and cyclosporin treatment in heart transplant recipients. Transplantation 1994; 58: 193–195.

    PubMed  Google Scholar 

  37. Ballantyne CM, Radovancevic B, Farmer JA et al. Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations. JACC 1992; 19: 1315–1321.

    Article  PubMed  CAS  Google Scholar 

  38. Levi M, Wilmink J, Büller HR, Surachno J, Wouter Ten Cate J. Impaired fibrinolysis in cyclosporin-treated renal transplant patients. Analysis of the defect and beneficial effect offish oil. Transplantation 1992; 54: 978–983.

    Article  PubMed  CAS  Google Scholar 

  39. Sams et al. Effect of fish oil on the graft vasculopathy in a rat model. J. Thorac. Cardiovasc. Surg. 1989; 97: 841–850.

    Google Scholar 

  40. Pflugfelder PW, Huff M, Oskalns R, Rudas L, Kostuk WJ. Cholesterol-lowering therapy after heart transplantation: a 12-month randomized trial. J. Heart Lung Transplant. 1995; 14: 613–622.

    PubMed  CAS  Google Scholar 

  41. Peters JR, Kubo SH, Olivari MT, Knutson KR, Hunninghake DB. Treatment of hyperlipidemia in heart transplant recipients with gemfibrozil± lovastatin. Am. J. Cardiol. 1993; 71: 1485–1488.

    Article  PubMed  CAS  Google Scholar 

  42. de Lorgeril M, Boissonnat P, Salen P, Monjaud I, Dureau G. Fenofibrate, probucol and other lipid-lowering treatment in heart transplant recipients. J. Heart Lung Transplant. 1996; 15: 539–540.

    PubMed  Google Scholar 

  43. Anderson JL, Schroeder JS. Effects of probucol on hyperlipidemic patients with cardiac allografts. J. Cardiovasc. Pharmacol. 1979; 1: 353–365.

    Article  PubMed  CAS  Google Scholar 

  44. Kobashigawa JA, Murphy FL, Stevenson LW et al. Low-dose lovastatin safely lowers cholesterol after cardiac transplantation. Circulation 1990; 82(suppl. IV): IV281–IV283.

    PubMed  Google Scholar 

  45. Kuo PC, Kirshenbaum JM, Gordon J et al. Lovastatin therapy for hypercholesterolemia in cardiac transplant recipients. Am. J. Cardiol. 1989; 64: 631–635.

    Article  PubMed  CAS  Google Scholar 

  46. Anguita M, Alonso-Pulpon L, Arizon JM et al. Comparison of the effectiveness of lovastatin therapy for hypercholesterolemia after heart transplantation between patients with and without pretransplant atherosclerotic coronary artery disease. Am. J. Cardiol. 1994; 74: 776–779.

    Article  PubMed  CAS  Google Scholar 

  47. East C, Alivizato PA, Grundy SM, Jones PH, Farmer JA. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation (letter). N. Engl. J. Med. 1988; 318: 47–48.

    Article  PubMed  CAS  Google Scholar 

  48. Norman DJ, Illingsworth DR, Munson J, Hosenpud J. Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin (letter). N. Engl. J. Med. 1988; 318: 46–47.

    Article  Google Scholar 

  49. Massy ZA, Guijarro C, Kasiske BL. Effect of fenofibrates in heart transplant patients (letter). Transplantation 1995; 59: 451.

    PubMed  CAS  Google Scholar 

  50. de Lorgeril M, Boissonnat P. Effect of fenofibrates in heart transplant patients (answer). Transplantation 1995; 59: 451–452.

    Google Scholar 

Download references

Authors
  1. Michel de Lorgeril
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Hospital Edouard Herriot, Pavillon V 5 Place d’Arsonval, F-69437, Lyon 3, France

    J. M. Dubernard

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

de Lorgeril, M. (1997). Lipid metabolism alteration and treatment in heart transplant recipients. In: Touraine, J.L., Traeger, J., Bétuel, H., Dubernard, J.M., Revillard, J.P., Dupuy, C. (eds) Late Graft Loss. Transplantation and Clinical Immunology, vol 28. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-5434-5_20

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-5434-5_20

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-6286-2

  • Online ISBN: 978-94-011-5434-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation